Abstract
After a quiet period of nearly 30 years, influenza strains with hemagglutinin types that have not been seen in humans previously started to jump from birds to man, suggesting the risk of a new influenza pandemic. However, in contrast to the situation with all the other influenza pandemics occurring in the 20th century and before, in the 21st century we have sophisticated technologies for diagnosis, therapy and prevention. Modeling of the possible spread of a pandemic suggests that vaccination is by far the only way to eliminate the risk of a new pandemic. In this chapter we review the development of new vaccines against H5N1 viruses, showing that effective vaccines adjuvanted with oil-inwater emulsion are about to be licensed and will soon be available. The race against an influenza pandemic has begun; it is a battle against time that mankind cannot afford to lose.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Deng G, Li Z, Tian G, Li Y, Jiao P, Zhang L, Liu Z, Webster RG, Yu K (2004) The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci USA 101: 10452–10457
Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M et al (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028–6036
Luke CJ, Subbarao K (2006) Vaccines for pandemic influenza. Emerg Infect Dis 12: 66–72
Suguitan, AL Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3: e360
Novavax Inc (2007) Press release Novavax announces preclinical results for seasonal influenza vaccine program
De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W (2005) Universal influenza A vaccine: Optimization of M2-based constructs. Virology 337: 149–161
De Filette M, Fiers W, Martens W, Birkett A, Ramne A, LÖwenadler B, Lycke N, Jou WM, Saelens X (2006) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24: 6597–6601
Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ et al (2007) Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccines 3: 157–164
Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13: 426–435
Livingston BD, Higgins D, Van Nest G (2006) Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs 20: 335–340
Nicholson KG, Colgate AE, Podda A, Stephenson I, Wood J, Ypma Y, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937–1943
Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M (2003) Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21: 1687–1693
Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy. J Infect Dis 191: 1210–1215
Schwatz B, Gellin B (2005) Vaccination strategies for an influenza pandemic. J Infect Dis 191: 1207–1209
Zangwill K, Campbell J, Noah D, Treanor J (2007) Evaluation of a third dose of subvirion H5N1 influenza vaccine (rgA/Vietnam/1203/04xPRB) in healthy adults. In: Options for the Control of Influenza VI (Toronto, June 17-23, 2007). Abstract no. P737
Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343–1351
Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O’Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19: 1732–1737
Bresson JL, Perronne L, Leunay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomized trial. Lancet 367: 1657–1664
Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-Roels G (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 370: 580–589
Banzhoff A (2007) Antigen-sparing effect of MF59 in Fluad-H5N1. In: Third WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials, 157#x2013;16 February 2007, WHO, Geneva
Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z et al (2006) Safety and immunogenicity of an inactivated adjuvanted wholevirion influenza A (H5N1) vaccine: A Phase I randomised controlled trial. Lancet 368: 991–997
Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I (2007) Inactivated whole virus influenza A (H5N1) vaccine. Emerg Infect Dis 13: 807–808
Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB (2006) Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43: 1135–1142
Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS (2005) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437: 209–214
Germann TC, Kadau K, Longini IM Jr, Macken CA (2006) Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 103: 5935–5940
Flahault A, Vergu E, Coudeville L, Grais RF (2006) Strategies for containing a global influenza pandemic. Vaccine 24: 6751–6755
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Rappuoli, R., Del Giudice, G. (2008). Waiting for a pandemic. In: Rappuoli, R., Del Giudice, G. (eds) Influenza Vaccines for the Future. Birkhäuser Advances in Infectious Diseases. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8371-8_12
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8371-8_12
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8370-1
Online ISBN: 978-3-7643-8371-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)